Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
Stack It With Pairs Well Gonadorelin Different axis (HPG vs
By reducing appetite and increasing feelings of fullness, semaglutide can help patients achieve sustainable weight loss
52 , 77887799 (2009) Serrano-Vega, M
US$ 21.61
US$ 28.24
US$ 21.41
US$ 20.56
US$ 27.98
